Considering the dual activation of both MEK and ER signaling pathways in gynecologic cancers, inhibition of the MEK pathway is a potential approach to sensitizing gynecologic cancers to endocrine therapy. This evidence concerns the gene ESR1 and female reproductive organ cancer.